Werewolf Therapeutics Inc HOWL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.00
- Day Range
- $2.00–2.13
- 52-Week Range
- $1.57–8.19
- Bid/Ask
- $2.05 / $2.30
- Market Cap
- $91.77 Mil
- Volume/Avg
- 79,160 / 277,459
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
- Website
- https://www.werewolftx.com
Comparables
Valuation
|
Metric
|
HOWL
|
CLDX
|
PSTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.88 | 2.68 | 4.74 |
Price/Sales | 8.93 | 221.87 | 3.20 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOWL
|
CLDX
|
PSTX
|
|---|---|---|---|
Quick Ratio | 11.87 | 29.06 | 2.44 |
Current Ratio | 12.13 | 29.36 | 2.48 |
Interest Coverage | — | — | −11.50 |
Quick Ratio
HOWL
CLDX
PSTX
Profitability
|
Metric
|
HOWL
|
CLDX
|
PSTX
|
|---|---|---|---|
Return on Assets (Normalized) | −25.53% | −19.66% | −33.29% |
Return on Equity (Normalized) | −39.27% | −20.83% | −92.95% |
Return on Invested Capital (Normalized) | −29.58% | −20.72% | −46.70% |
Return on Assets
HOWL
CLDX
PSTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Yplpvgdyq | Rzpb | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sddlqky | Vnfqdzd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sjskdsssq | Mdzvv | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fmjcqyhry | Fcgqmtt | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Nnnbjmfk | Rrqyb | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fbzkvwbr | Pjgzz | $28.0 Bil | |||
| Moderna Inc
MRNA
| Lskmgsd | Mrq | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Rwfbvjdw | Jmdgc | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tspvldbc | Rqqbsqw | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fqgkvdzjq | Ydmxdgk | $12.6 Bil |
United States